At first glance, I didn't like Merck's ( MRK ) case very much. It is highly dependent on a drug whose patent will expire around 2028; due to its industry, it has many uncertainties in its pipeline, R&D expenses, a certain dependence on the government, and soEquity Research Analyst with a broad career in the financial market, covered both Brazilian and global stocks. As a value investor, my analysis is primarily fundamental, focusing on identifying undervalued stocks with growth potential. Feel free to reach ...